Hyperbaric oxygen therapy for Alzheimer’s dementia with positron emission tomography imaging

The prevalence and costs of dementia, of which Alzheimer’s dementia (AD) is the dominant subtype, are substantial. AD is characterized by deficits in memory and executive function. Treatments have focused on pharmacotherapy, but from 2002–2012 the US Food and Drug Administration has cleared only 1 of 244 drugs tested6 and no therapy halts disease progression.


By continuing to browse you are agreeing to our use of cookies as explained in our Cookie Policy.

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn Social Icon

Hyperbaric Medicine International (HMI)  |  PO Box 450 Westtown, PA 19395-0450  |  484-639-9006

© Copyright 2019-2020 Hyperbaric Medicine International, all rights reserved. HMI is a 501(c)(4) Information provided by Hyperbaric Medicine International does not constitute medical diagnosis or recommendations, and is intended for informational purposes only.